Benoit C, Beschin A, Desmecht M, Dekeyser P, Cocito C
Microbiology and Genetics Unit, ICP, University of Louvain Medical School, Brussels, Belgium.
Med Microbiol Immunol. 1989;178(2):105-12. doi: 10.1007/BF00203306.
Antigen A60 has been purified from the cytoplasm of Mycobacterium bovis BCG, and its composition has been determined: it has proved to be able to elicit immune reactions of both humoral and cellular type. Inoculation of A60 into the footpad of mice previously sensitized with the same antigen, or with whole mycobacterial cells produced a footpad swelling showing a peak at 24 h. Similar delayed hypersensitivity reactions were induced in sensitized guinea-pigs by subcutaneous injection of an A60 dose of 0.01 micrograms (minimal revealing dose). A quantity thousandfold higher (15 micrograms A60) was unable to induce in unsensitized guinea pigs the mounting of a cellular immunisation against A60, as shown by negative cutaneous testings 1 month later. Our results show that A60 preparations satisfied the requirements of the European Pharmacopoeia Commission and met the WHO recommendations for new tuberculins. Handicaps of old tuberculin and PPD (heterogeneous mixtures titrated biologically and unstable in solution) can be overcome by A60 preparations (a single antigen spectrophoretically measurable and stable).
抗原A60已从卡介苗的细胞质中纯化出来，其成分已确定：它已被证明能够引发体液免疫和细胞免疫反应。将A60接种到先前用相同抗原或全部分枝杆菌细胞致敏的小鼠脚垫中，会引起脚垫肿胀，在24小时达到峰值。通过皮下注射0.01微克A60剂量（最小显效剂量），在致敏豚鼠中诱导出类似的迟发型超敏反应。1个月后皮肤测试呈阴性，表明15微克A60（高出一千倍的量）无法在未致敏的豚鼠中诱导针对A60的细胞免疫反应。我们的结果表明，A60制剂符合欧洲药典委员会的要求，并符合世界卫生组织对新型结核菌素的建议。旧结核菌素和PPD（通过生物学滴定的异质混合物且在溶液中不稳定）的缺点可以通过A60制剂（单一抗原，可通过光谱法测量且稳定）克服。
Zotero 插件